Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis

作者：Ana Catalán, Gonzalo Salazar de Pablo, Clàudia Aymerich, Stefano Damiani, Veronica Sordi, Joaquim Raduà, Dominic Oliver, Philip McGuire, Anthony J. Giuliano, William S. Stone, Paolo Fusar‐Poli · 发表于：JAMA Psychiatry · 年份：2021 · DOI：10.1001/jamapsychiatry.2021.1290 · 被引用次数：219 · 研究领域：Schizophrenia research and treatment、Tryptophan and brain disorders、Dementia and Cognitive Impairment Research

IMPORTANCE: Neurocognitive functioning is a potential biomarker to advance detection, prognosis, and preventive care for individuals at clinical high risk for psychosis (CHR-P). The current consistency and magnitude of neurocognitive functioning in individuals at CHR-P are undetermined. OBJECTIVE: To provide an updated synthesis of evidence on the consistency and magnitude of neurocognitive functioning in individuals at CHR-P. DATA SOURCES: Web of Science database, Cochrane Central Register of Reviews, and Ovid/PsycINFO and trial registries up to July 1, 2020. STUDY SELECTION: Multistep literature search compliant with Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology performed by independent researchers to identify original studies reporting on neurocognitive functioning in individuals at CHR-P. DATA EXTRACTION AND SYNTHESIS: Independent researchers extracted the data, clustering the neurocognitive tasks according to 7 Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) domains and 8 CHR-P domains. Random-effect model meta-analyses, assessment of publication biases and study quality, and meta-regressions were conducted. MAIN OUTCOMES AND MEASURES: The primary effect size measure was Hedges g of neurocognitive functioning in individuals at CHR-P (1) compared with healthy control (HC) individuals or (2) compared with individuals with first-episode psychosis (FEP) or (3) s...